Background/Aims: We have so far demonstrated the renoprotective effect of camostat mesilate (CM) in 5/6 nephrectomized rats at least partly through its antioxidant effect. However, precise mechanisms were not fully clarified. Therefore, we now examined the renoprotective and antioxidant mechanisms of CM by using the adenine-induced chronic kidney disease (CKD) rat model. Methods: In protocol 1, we analyzed the effect of CM on CKD. Rats were fed on a 0.75% adenine diet for 3 weeks to induce CKD followed by the experimental period with vehicle, CM, or hydralazine (HYD) treatment for 5 weeks. In protocol 2, we examined the safety of CM and HYD on the normal rats. In addition, we explored free radical scavenging activities of CM and its metabolites in vitro using electron paramagnetic resonance (EPR) spectroscopy. Results: CM, but not HYD, significantly reduced the serum creatinine levels, although both treatments showed similar reduction in the blood pressure. CM decreased mRNA expression and protein levels of fibrotic markers, the severity of renal fibrosis, the accumulation of oxidative stress, and the expression of NADPH oxidase components in the kidney. In the protocol 2, there were no statistically significant differences in general parameters except for the systolic blood pressure in HYD group. EPR study revealed that CM and its metabolites have potent hydroxyl radical scavenging activities in vitro. Conclusion: Our findings indicate that CM significantly ameliorates the progression of CKD partly through its antioxidant effect independently from its blood pressure-lowering effect. Our results suggest the possibility that CM could be a new therapeutic agent that could arrest the progression of CKD.

Keywords:
Chronic kidney diseases, Serine protease inhibitor, Antioxidant effect, Free radical scavenger
1.
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247-259.
2.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
3.
Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97.
4.
Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D: Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006;48:752-760.
5.
Shah SV: Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 1989;35:1093-1106.
6.
Manning RD Jr, Tian N, Meng S: Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol 2005;25:311-317.
7.
Hayata M, Kakizoe Y, Uchimura K, Morinaga J, Yamazoe R, Mizumoto T, Onoue T, Ueda M, Shiraishi N, Adachi M, Miyoshi T, Sakai Y, Tomita K, Kitamura K: Effect of a serine protease inhibitor on the progression of chronic renal failure. Am J Physiol Renal Physiol 2012;303:F1126-F1135.
8.
Ali BH, Al-Husseni I, Beegam S, Al-Shukaili A, Nemmar A, Schierling S, Queisser N, Schupp N: Effect of gum Arabic on oxidative stress and inflammation in adenine-induced chronic renal failure in rats. PLoS One 2013;8:e55242.
9.
Nicholas SB, Yuan J, Aminzadeh A, Norris KC, Crum A, Vaziri ND: Salutary effects of a novel oxidative stress modulator on adenine-induced chronic progressive tubulointerstitial nephropathy. Am J Transl Res 2012;4:257-268.
10.
Yokozawa T, Zheng PD, Oura H, Koizumi F: Animal model of adenine-induced chronic renal failure in rats. Nephron 1986;44:230-234.
11.
Suzuki J, Suzuki S, Nozawa R, Kumaki S, Kume K, Higuchi E, Kamiyama S, Ohara N, Yugeta E, Kato K, et al: Effect of camostat mesilate on puromycin aminonucleoside nephrotic rats. Fukushima J Med Sci 1988;34:21-25.
12.
Ishikura H, Nishimura S, Matsunami M, Tsujiuchi T, Ishiki T, Sekiguchi F, Naruse M, Nakatani T, Kamanaka Y, Kawabata A: The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents. Life Sci 2007;80:1999-2004.
13.
Beckh K, Göke B, Müller R, Arnold R: Elimination of the low-molecular weight proteinase inhibitor camostate (FOY 305) and its degradation products by the rat liver. Res Exp Med 1987;187:401-406.
14.
Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
15.
Miyamoto Y, Iwao Y, Tasaki Y, Sato K, Ishima Y, Watanabe H, Kadowaki D, Maruyama T, Otagiri M: The uremic solute indoxyl sulfate acts as an antioxidant against superoxide anion radicals under normal-physiological conditions. FEBS Lett 2010;584:2816-2820.
16.
Geiszt M: NADPH oxidases: new kids on the block. Cardiovasc Res 2006;71:289-299.
17.
Halliwell B: Oxidants and human disease: some new concepts. FASEB J 1987;1:358-364.
18.
Alfrey AC, Froment DH, Hammond WS: Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989;36:753-759.
19.
Fischer UM, Tossios P, Mehlhorn U: Renal protection by radical scavenging in cardiac surgery patients. Curr Med Res Opin 2005;21:1161-1164.
20.
Thakur V, Walker PD, Shah SV: Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria. Kidney Int 1988;34:494-499.
21.
Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z: Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 2007;73:1499-1510.
22.
Shimizu H, Bolati D, Adijiang A, Enomoto A, Nishijima F, Dateki M, Niwa T: Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am J Physiol Cell Physiol 2010;299:C1110-C1117.
23.
Motoo Y: Antiproteases in the treatment of chronic pancreatitis. JOP 2007;8(4 suppl):533-537.
24.
Kono K, Takahashi A, Sugai H, Umekawa T, Yano T, Kamiyasu K, Teramatsu M, Fujii H: Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity. Am J Surg 2005;190:412-417.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.